

File No: 1010/1 26<sup>th</sup> March, 2023

BSE Limited P J Towers, Dalal Street, Fort Mumbai-400001 Scrip Code: 542216 National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051
Symbol: DALBHARAT

Sub: Disclosure of sale of equity stake in Dalmia Bharat Refractories Limited

**Ref:** Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(SEBI LODR).

Dear Sir/Madam,

We wish to inform you that in line with its strategy to exit non-core business/investment and pursuant to the approval granted by its Board of Directors in its meeting held on 25<sup>th</sup> March, 2023, Dalmia Cement (Bharat) Limited (DCBL), a material wholly owned subsidiary of the Company, has entered into a binding agreement to sell its entire investment of 1,87,23,743 equity Shares of Rs. 10 each (42.36% of share capital) of Dalmia Bharat Refractories Limited (DBRL), an associate company, at a consideration of Rs. 800 cr. to M/s Sarvapriya Healthcare Solutions Private Limited (Sarvapriya), a promoter group Company.

The transaction will be consummated within 30 days i.e. on or before 25<sup>th</sup> April, 2023 and the consideration for transfer of investment shall be received by DCBL as follows:

		RS. Cr.
-	20% payment on the date of consummation of transaction	160
-	40% by way of NCDs redeemable on or before 31st Dec, 2023	320
-	40% by way of NCDs redeemable on or before 30 <sup>th</sup> Sept, 2024	320

The NCDs will carry coupon of 8.5% p.a. payable quarterly.

The letter received from DCBL in the regard is attached for reference.

In reference to above, this is to also inform you that the Company will hold an Investors/Analysts Conference Call on Monday, 27<sup>th</sup> March, 2023 at 10:30 A.M. (IST), a copy of invite is attached.

## Dalmia Bharat Limited



This is for your information and records.

Thanking you,

Yours sincerely,
For Dalmia Bharat Limited

Rajeev Kumar Company Secretary Encl: As above



**FUTURE TODAY** 

March 26, 2023

To
The Compliance Officer,
Dalmia Bharat Limited
11th & 12th Floors, Hansalaya Building,
15, Barakhamba Road,
New Delhi-110 001

Sub: Intimation regarding sale of equity stake in Dalmia Bharat Refractories Limited (DBRL)

Dear Sir/Madam,

We wish to inform you that in line with its strategy to exit non-core business/investments and pursuant to the approval granted by the Board of Directors of the Company at its meeting held on March 25, 2023, the Company has today entered into a binding agreement to sell its entire investment of 1,87,23,743 equity Shares of Rs. 10 each (42.36% of share capital) of Dalmia Bharat Refractories Limited (DBRL), an associate company, to Sarvapriya Healthcare Solutions Private Limited (Sarvapriya), a promoter group Company, at a consideration of Rs. 800 Crore.

The transaction will be consummated within 30 days i.e. on or before 25<sup>th</sup> April, 2023 with payment to be received as follows:

		Rs. Crore
-	20% payment on the date of consummation of transaction	160
-	40% by way of NCDs redeemable on or before 31st Dec, 2023	320
-	40% by way of NCDs redeemable on or before 30 <sup>th</sup> Sept, 2024	320

The NCDs will carry coupon of 8.5% p.a. payable quarterly.

The disclosure as may be required under SEBI LODR Regulations is attached hereto for your reference.

This is for your information and records.

Thanking you,

Yours sincerely,

For Dalmia Cement (Bharat) Limited

Manisha Bansal Company Secretary

**Encl: As above** 



## **FUTURE TODAY**

Information required under para A in part A of schedule III of SEBI LODR read with SEBI circular dated September 9, 2015

SL No	Particulars	Details
a)	the amount and percentage of the	Not Applicable
	turnover or revenue or income and	
	net worth contributed by such unit or	
	division of the listed entity during the	
	last financial year;	
b)	date on which the agreement for sale	Expected date 26 <sup>th</sup> March, 2023
	has been entered into;	
c)	the expected date of completion of sale/disposal;	On or before 25th April, 2023
d)	consideration received from such	Rs. 800 Crore consideration to be received as
	sale/disposal;	follows:
		Rs.
		Crore.
		20% on date of consummation 160
		40% by NCDs redeemable on or before 31st Dec, 2023
		40% by NCDs redeemable on or
		before 30th Sept, 2024 320
e)	brief details of buyers and whether	Sarvapriya Healthcare Solutions Private Limited, a
	any of the buyers belong to the	promoter group Company.
	promoter/ promoter group/group	
	companies. If yes, details thereof;	
-		
f)	whether the transaction would fall	Yes, the transaction is a related party transaction
	within related party transactions? If	and the transaction is entered into on "arm's
	yes, whether the same is done at "arm's length";	length" basis, and as approved by the Board based on recommendation of Independent Directors and
	aiiii s ieiigiii ,	the Audit Committee after relying on various
		inputs, incl. Valuation Report by registered valuer.
g)	additionally, in case of a slump sale,	Not Applicable
8,	indicative disclosures provided for	
	amalgamation/ merger, shall be	
	disclosed by the listed entity with	
	respect to such slump sale.	

## The Management team of Dalmia Bharat Limited

invites you to a

Conference Call on Business Update on Monday, 27<sup>th</sup> March 2023, 10:30 am (IST)



## **Dial-in Numbers**

<u>Primary Number:</u> +91 22 6280 1536 <u>Secondary Number:</u> +91 22 7115 8344

**India Toll Free Numbers** – 1 800 120 1221

<u>International Toll Free Numbers</u> - USA: 1 866 746 2133 / UK: 0 808 101 1573 / Singapore: 800 101 2045

/ **Hong Kong:** 800 964 448

Pre register to avoid wait time, join with DiamondPass. Click here to register